Protocolo de atención y pronóstico de los pacientes con diagnóstico de glioblastoma cerebral postquirúrgica precoz

Kelly Nicole Cruz Córdova, Sonia Gabriela Cevallos Ávila, Jonathan Miguel Carpio Bravo, Ericka Paola Pazmiño Rodríguez

Resumen


El glioblastoma es un tipo de cáncer que comienza con el desarrollo de células en el cerebro o en la médula espinal, que brindan sostén a las células nerviosas. Las células se desarrollan rápidamente, y pueden invadir y destruir tejidos sanos. El glioblastoma se forma a partir de células denominadas astrocitos, que brindan soporte a las neuronas. Puede ocurrir a cualquier edad, pero tiende a aparecer con mayor frecuencia en adultos mayores y en hombres. Los síntomas del glioblastoma incluyen dolores de cabeza que empeoran, náuseas y vómitos, visión borrosa o doble y convulsiones. No existe cura para el glioblastoma, también llamado glioblastoma multiforme. Los tratamientos pueden reducir la velocidad de desarrollo del cáncer y disminuir los síntomas.


Palabras clave


Glioblastoma; cerebro; médula espinal; células nerviosas; glioblastoma multiforme.

Texto completo:

PDF HTML

Referencias


Han M.D; Michael E; Surgnme. H. The Rise and Fall of “Biopsy and Radiate”. A History of Surgical Nihilism in Glioma treatment. Neurosurgery Journal 23 (2022) 207-214.

Reyes Oliveros F; Lema Bouzas M. Gliomas del encéfalo. Universidad Santiago de Compostela, ed: Campus universitario sur Santiago Compostela, 2019.

Greenberg Mark S. Handbook of Neurosurgery, Seventh Edition 2020.

Romper A.H; Brown R.H. Adam’s and Victor’s Principles of Neurology, New Cork. Mc Graw-Hill; 2005; 546-591.

Handbook of Neurosurgery, seventh Edition, Chapter 21, Tumor 2010.

Lucas J; Zada Gabriel; Radiology: Criteria for Determining Response to treatment and recurrence of high-grade gliomas. Neurosurgery Clin North American 23 (2022) 269-276.

Fulci G et al; p53 gene mutation and INK4-ARF deletion appear to be mutually exclusive events in human glioblastoma. Oncogene 2020; 19: 3816-3822.

Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nature Rev. Cancer 2002, 2: 616-626.

Sansón M, Thillet J, Hoang-Xuan K. Molecular changes in gliomas. Curr. Opin. Oncol. 2004, 16 : 607-613.

Esteller M, García-Foncillas J, Andino E et al. Inactivation of the DNArepair gene MGMT and the clinical response of gliomas to alkylating agents. N. England Jounal Medical. 2020; 343: 1350-1354.

Alaminos M, Dávalos V, Ropero S. el al. EMP3; a myelin – related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor supresor in glioma and neuroblastoma. Cancer Res. 2005; 65: 2565-2571.

Shmimizu H, Kumabe T. Shirane R, et al. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labelig index in gliomas. AJNR 2000; 21: 659-665.

Nagasawa D, Chow F, Yew A, Kim W, et al. Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurgery Clinic North American 23 (2012) 271-284. 18

Grang F, Cerdá M, Piquer J, Reynes G. Recomendaciones sobre la atencion multidisciplinar del paciente con glioma maligno. Med. Clinica 2001; 116: 271-275.

Jahangiri A, Manis K, Aghi. Pseudoprogression and Treatment effect. Neurosurgery Clinic North American 23 (2017) 277- 288.

Stupp R, Mason WP, van den Bent MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2015;352:987–96,

Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376:1027–37

Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709–22

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708,

Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2066;148:269–75, discussion 275.

Grangeon L, Ferracci F-X, Fetter D, Maltete D, Langlois O, Gilard V. How safe are carmustine wafers? Rev Neurol (Paris). 2018;174:346–51, https://doi.org/10.1016/j.neurol.2017.09.011.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 2017;318:2306–16

Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer. 2020; 20:12–25, https://doi.org/10.1038/s41568-019-0224-7.

Adhikaree J, Moreno-Vicente J, Kaur AP, Jackson AM, Patel PM. Resistance mechanisms and barriers to successful immunotherapy for treating glioblastoma. Cells. 2020; 9:263

Inogés S, Tejada S, Cerio ALD, Gállego Pérez-Larraya J, Espinós J, Idoate MA, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med. 2017;15:104

Stepanenko AA, Chekhonin VP. Recent advances in oncolytic virotherapy and immunotherapy for glioblastoma: A glimmer of hope in the search for an effective therapy? Cancers (Basel). 2018;10, 492.https://doi.org/10.3390/cancers10120492.

Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res. 2019;38:87

Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial CheckMate-143: The game is not over yet. Oncotarget. 2017;8:91779–94

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:1373–85

Strebe JK, Lubin JA, Kuo JS. Tag Team Glioblastoma Therapy: Results from a phase 1 trial of toca 511 and 5-fluorocytosine for recurrent high-grade glioma. Neurosurgery. 2016;79, https://doi.org/10.1227/01.neu.0000508605.38694.fd N18-N20.

Lu VM, Jue TR, McDonald KL, Rovin RA. The survival effect of repeat surgery at glioblastoma recurrence and its trend: A systematic review and meta-analysis. World Neurosurg. 2018;115:453–9




DOI: https://doi.org/10.23857/pc.v9i2.6915

Enlaces de Referencia

  • Por el momento, no existen enlaces de referencia
';

Bookmark and Share




Polo del Conocimiento              

Revista Científico-Académica Multidisciplinaria

ISSN: 2550-682X

Casa Editora del Polo                                                 

Manta - Ecuador       

Dirección: Ciudadela El Palmar, II Etapa,  Manta - Manabí - Ecuador.

Código Postal: 130801

Teléfonos: 056051775/0991871420

Email: polodelconocimientorevista@gmail.com / director@polodelconocimiento.com

URL: https://www.polodelconocimiento.com/